We should all now encourage more brokers to cover TIS and the media to promote it as well. It will be in everybody's interest, including existing and potential shareholders, and ulcer sufferers. So I suggest that each of us writes to their broker along the following lines, and also send this to relevant media. The following text is an example of what you could send, but feel free to change it as you think necessary:
I strongly believe that you would be providing your clients with some excellent service if you were to add Tissue Therapies (TIS) to the stocks that you analyse and report on. My reasons for saying this are:
1. TIS's VitroGro is within 12 months of commencing sales in Europe; closely followed by other markets;
2. VitroGro has already been proven to be the only product which successfully heals ulcers that do not respond to existing treatments. The most recent trial results found that 92 percent of the patients taking part in the trial were partially or completely healed in 12 weeks. The average reduction in wound size was 65 percent, with no adverse events related to VitroGrow reported.
3. VitroGro is classified in Canada and Europe as a medical device, not a drug. This greatly simplifies and de-risks the upcoming approvals. Similar classification in USA has been sought from FDA.
4. TIS is close to concluding a partnership deal for sales and marketing, but will control manufacturing and approvals.
5. The ulcer market alone is estimated by the TIS Board to be worth $30B by 2014 and growing at 25% per annum.
6. VitroGro is likely to also sell into other markets including scar and burns remediation, pharmacy and consumer products for cuts and burns.
7. Revenue will start to flow to TIS by mid 2012 together with milestone payments from its partner.
In conclusion, TIS appears to be the next major Australian bio-share success story within 12 months. I am sure your brokerage would not wish to be late to this party. For additional information please refer to the following links about TIS and VitroGro: